Grape King Bio Ltd. (1707) AI Stock Analysis

Grape King Bio Ltd.

(TWSE:1707)

Select Model

Rating:65Neutral

Price Target:TWD 87.00▲(10.41% Upside)

Action:initiatedcoverage

Date:11/10/26

The overall score of 65 reflects a company with strong financial health and compelling valuation that is currently under severe technical pressure. The most significant positive factors are the rock-solid balance sheet and the very attractive 7.45% dividend yield, which is supported by a low P/E ratio. However, these are offset by a clear downtrend in financial performance and deeply bearish technical momentum, with the stock in a sustained decline below all major moving averages. The company is a high-quality business facing operational headwinds, creating a tension between its fundamental value and negative market sentiment.

Positive Factors

Strong ProfitabilityConsistently high gross margins and healthy operating margins indicate that Grape King retains substantial economics after production costs. This provides resilience against moderate cost pressure, supports ongoing investment in functional products, and gives the business a durable base for profitability over the next several quarters.

Negative Factors

Revenue DeclineThe return to revenue contraction indicates that recent demand and sales momentum have weakened, limiting operating leverage and the company’s ability to grow earnings through expansion. If this persists, it could reduce investment capacity and make future profit growth increasingly dependent on cost control.

Grape King Bio Ltd. (1707) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 11.72B
Dividend Yield: 7.61%
Average Volume (3M): 384.05K
Price to Earnings (P/E): 11.0
Beta (1Y): 0.12
Revenue Growth: -5.38%
EPS Growth: -12.85%
Country: TW
Employees: 501
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Grape King Bio Ltd. Business Overview & Revenue Model

Company Description

Grape King Bio Ltd. is a Taiwanese enterprise specializing in the production and distribution of a diverse array of health-focused items, encompassing pharmaceuticals, traditional remedies, nourishing beverages, and dietary supplements. Its market pr...

Grape King Bio Ltd. Financial Statement Overview

Summary

Grape King Bio's financial foundation is robust, anchored by a fortress-like balance sheet with negligible debt and consistent cash flow generation. However, a clear declining trend in revenue, net income, and free cash flow since 2022, coupled with compressing margins, signals operational headwinds. The overall financial health is strong, but the negative earnings trajectory tempers the score.

Income Statement

62Positive

Balance Sheet

85Very Positive

Cash Flow

70Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	10.12B	10.25B	11.16B	10.64B	10.39B	9.80B
Gross Profit	7.38B	7.70B	8.66B	8.54B	8.48B	7.86B
EBITDA	2.63B	2.69B	3.17B	3.12B	3.13B	2.83B
Net Income	1.15B	1.22B	1.45B	1.45B	2.17B	1.95B
Balance Sheet
Total Assets	15.00B	15.74B	15.32B	15.51B	15.05B	14.06B
Cash, Cash Equivalents and Short-Term Investments	3.70B	4.28B	4.43B	4.97B	4.79B	3.90B
Total Debt	186.69M	215.03M	160.91M	192.92M	157.75M	271.76M
Total Liabilities	3.40B	3.67B	3.53B	3.88B	3.91B	3.63B
Stockholders Equity	10.24B	10.34B	10.06B	9.98B	9.57B	8.99B
Cash Flow
Free Cash Flow	1.50B	1.73B	1.23B	1.92B	2.49B	2.26B
Operating Cash Flow	1.99B	2.18B	1.88B	2.52B	2.99B	2.54B
Investing Cash Flow	-724.19M	-580.08M	-662.11M	-654.73M	-330.31M	-462.34M
Financing Cash Flow	-1.62B	-1.77B	-1.72B	-1.71B	-1.63B	-1.37B

Grape King Bio Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:1707 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:8462	68Neutral	TWD 11.77B	12.93	―	4.84%	19.42%	56.92%
TW:1707	65Neutral	TWD 11.66B	10.97	―	7.61%	-5.38%	-12.85%
TW:8436	62Neutral	TWD 10.59B	10.40	―	6.64%	-3.82%	2.23%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:1234	54Neutral	TWD 12.82B	19.36	―	5.20%	-2.63%	-20.48%
TW:6617	40Underperform	TWD 16.13B	-94.81	―	―	11.66%	-72.96%

* General Sector Average

Performance Comparison

TW:1707 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:1707	Grape King Bio Ltd.	78.80	-44.23	-35.95%
TW:1234	Hey-Song Corp.	31.75	-3.69	-10.42%
TW:6617	Gongwin Biopharm Holdings Co., Ltd.	128.00	43.40	51.30%
TW:7780	Daiken Biomedical Co., Ltd.	14.90	-2.35	-13.61%
TW:8436	TCI Co., Ltd.	90.60	-23.20	-20.38%
TW:8462	Power Wind Health Industry Incorporated	150.50	3.31	2.25%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

Grape King Bio Ltd. AI Stock Analysis